Related Experiment Video
Updated: Dec 17, 2025

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs
Published on: December 27, 2016
Immunomodulatory Agents in Follicular Lymphoma
Loic Ysebaert1, Franck Morschhauser2
1Service d'Hematologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Center for Cancer Research of Toulouse (CRCT), Inserm UMR1037, IUC-Toulouse-Oncopole, 1 Avenue Irene Joliot-Curie, Toulouse 31059, France.
New follicular lymphoma (FL) treatments leverage understanding of the tumor microenvironment. Lenalidomide combined with anti-CD20 antibodies shows promise as an alternative to chemoimmunotherapy (CIT).
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Follicular lymphoma (FL) pathogenesis is influenced by microenvironmental factors.
- Immune-mediated signaling pathways are key to lymphomagenesis and treatment resistance.
- Lenalidomide represents a novel oral immunomodulatory drug for FL treatment.
Purpose of the Study:
- To review the biological rationale for targeting the FL immune microenvironment.
- To explore novel immunomodulating combinations as alternatives to chemoimmunotherapy (CIT).
Main Methods:
- Review of current literature on FL biology and treatment strategies.
- Analysis of clinical data for lenalidomide-based combinations.
- Evaluation of immune-mediated signaling pathways in FL.
Main Results:
- Lenalidomide combined with rituximab demonstrates comparable efficacy to CIT in first-line FL.
- This combination is approved for relapsed/refractory FL.
- Targeting inhibitory receptor/ligand pathways in the FL microenvironment is a promising strategy.
Conclusions:
- Understanding the FL immune microenvironment drives new therapeutic strategies.
- Lenalidomide-based regimens offer a non-chemotherapeutic option for FL.
- Future treatments may involve novel immunomodulating combinations to replace CIT.
More Related Videos
07:04Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
07:07Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice
Published on: June 27, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...